SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compounds institutional pivotincluding a treasury-backed finance program, new leadership and an institutional market launchis fueling interest, alongside anticipation of a technical breakout tied to COMPs capped supply. Bulls see room for a rebound, while skeptics point to weak price action and concerns about liquidity and the protocols prospects.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Discussion centers on real-world evidence for CorMedixs DefenCath versus ClearGuard: bullish traders point to infection reductions in some studies and subgroups, while skeptics highlight Fresenius results showing no significant overall difference and question whether DefenCath justifies its higher cost. The debate feeds into broader uncertainty about DefenCath adoption and reimbursement after the temporary TDAPA payment period.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

WLDs sharp rally and perceived technical breakout are drawing attention, with traders highlighting Eightco/ORBSs reported 8.4% stake in the token as a source of treasury-related interest. Some also point to Worldcoins proof-of-humanity angle amid AI growth, while ETF and further-upside expectations remain speculative.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

Michael Burrys disclosed QXO stake sparked renewed attention and a rally, with traders speculating about short covering and a squeeze. Others view the move as potentially temporary and remain concerned about high rates, weak housing conditions, and the companys acquisition-related dilution.

Armada Acquisition Corp. II is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combinations with one or more businesses. The company was founded on October 3, 2024 and is headquartered in Miami, FL.

Armada Acquisition Corp. II - Ordinary Shares- Class A

Evernorth Holdings Inc.

Shareholder approval of Evernorths merger with Armada and its planned Nasdaq debut as an XRP treasury company are driving attention, with the company expected to hold a large XRP reserve. Traders are reacting to a sharp, volatile rally and possible tight-float squeeze, while debating whether the stocks premium to its XRP holdings is justified and warning of profit-taking risk.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRXs sharp, high-volume breakout and close above a long-standing resistance level drew attention despite no confirmed company announcement. Traders attribute the move to possible institutional buying and short covering, while also speculating about upcoming Anktiva regulatory and commercial catalysts; the squeeze theories remain unconfirmed.

Core Scientific, Inc. engages in the business of operating a purpose-built facility for digital asset mining and provision of blockchain infrastructure, software solutions, and services. It operates under the Mining and Hosting segments. The Mining segment focuses on bitcoin mining for the company's own account. The Hosting segment includes blockchain infrastructure and third-party hosting business. The company was founded by Michael Jeffrey Levitt and Darin Feinstein on December 13, 2017 and is headquartered in Dover, DE.

Core Scientific Inc - Ordinary Shares - New

Core Scientific Inc

Discussion centers on Core Scientifics shift from Bitcoin mining toward AI/HPC data centers, with traders citing AMD and CoreWeave capacity commitments and bullish analyst coverage. Some expect improving HPC revenue and a return to profitability around upcoming earnings, while others remain wary of weak price action and execution risk.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is drawing attention amid a cybersecurity-sector rally tied to rising AI-related threat concerns, with traders also citing bullish analyst target increases and the stocks recent breakout. Many see its valuation as low relative to peers and speculate about a potential acquisition, while skeptics question its ability to sustain growth and keep pace with CrowdStrike; takeover talk remains speculation.

What is the project about? Vara Network is a substrate-based future proof smart contract platform that is fast, scalable, and makes it simple to create and deploy next-generation Web3.0 dApps Vara is the first standalone network in the Gear Protocol  Gear is a next-gen cloud infrastructure platform providing most intuitive and frictionless environment for web2 and web3 developers to build complex infrastructure solutions and disruptive dApps for any ecosystem  What makes your project unique? Vara is built upon three core concepts: The actor model, and persistent memory — two widely adopted primitives from massive computation and microservices architecture spaces  Wasm — a WebAssembly-based virtual machine that runs on all modern browsers. Proven to be faster than any alternative web2 virtual machines  Vara was created to serve as a wasm-native hub for innovative protocols that leverage parallel execution and asynchronous programming to deliver leading decentralized products in any segment  History of your project. Gear Protocol and the Vara Network were originally created by Nikolay Volf, one of the core developers of Polkadot. In 2021, he embarked on building an advanced layer 1 smart contract platform using Substrate, Polkadot's custom framework. His vision included creating a platform that enables fast and efficient execution of robust, feature-rich dApps while in a seamless development environment similar to that of Web 2.0 development. He did this by  harnessing the power of innovative technologies like Wasm, the Actor Model, and Persistent Memory. These technologies significantly enhance smart contract development and provide a seamless end-user experience and provide the foundation for the development of Vara Network.  1. Q2 2021 - Pre-Seed Round: In the second quarter of 2021, the Protocol secured its initial funding through a pre-seed round. This likely involved seeking investment from early-stage investors or venture capitalists to kickstart the development of the project.  2. Q4 2021 - Seed Round: In December 2021 raised $12 Million in Venture Round. Private investment round led by Blockchange Venture. In addition to Blockchange, other top venture capital funds participated in this round, including Three  Arrows Capital, Lemniscap, Distributed Global, LAO, Mechanism Capital, Bitscale, Spartan Group LLC, HashKey, DI Ventures, Elysium Venture Capital, Signum Capital and P2P Economy lead by Konstantin Lomashuk, along with a number of top executives of Web3 Foundation and Parity Technologies. Dr. Gavin Wood, Founder and ex-CEO of Parity Technologies and one of the key individual investors participating in this round.  3. 2022 - Intensive Scaling and Development, First Test Integrations: Throughout the year 2022, Vara was focused on two primary activities. First, the engagement in an extensive outreach process to build up the team. Second, the project advanced its technical development efforts and started working on integrating their technology with various test environments to ensure its functionality and viability.  4. Q4 2022 - Testnet Launch.   5. Q1 2023 - PoA Launch: In the first quarter of 2023, Vara achieved launch of its Proof of Authority (PoA) consensus network, which is a chain candidate for mainnet.  Current Status of Vara:  Presently, the project boasts a talented and diverse decentralized workforce, consisting of dozens of engineers and other community members  to drive the project's success.  One of the remarkable aspects of Vara is its substantial pipeline of initiatives with over 40 projects.  What’s next for your project? Current projects being researched and developed by the community:  - Intensive testing and improvement of the actor model features in the blockchain space  - Launch of the key stack of dApps in our parallel and asynchronous environment   - Development of innovative infrastructure solutions (e.g offchain zk actors including machine learning) independently and together with the segment leaders  What can your token be used for? VARA tokens maintain core utility features required for the network to operate: transaction fees staking and network security governance other: gas pools for gas reservation  Contributors to the Gear protocol are exploring the mechanics of how to distribute a portion of block rewards directly toward dApp developers

Vara Network

VARA is drawing attention amid volatile trading and hopes for a rebound from its prolonged decline, with traders pointing to rising volume and possible technical breakouts. The debate centers on whether slowing token unlocks and network developments, including an Ethereum bridge and new projects, can offset dilution concerns and a history of sharp pump-and-dump swings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA filing for sonelokimab in hidradenitis suppurativa has shifted attention to whether the FDA will accept the application and grant priority review. The filing has drawn a muted reaction amid continued share-price weakness, with traders debating clinical differentiation after recent trial results, dilution and managements plan to commercialize independently versus pursue a partnership or sale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot

The move appears tied to renewed retail attention to biotech after Modernas rally and upcoming Nasdaq-100 inclusion, with traders comparing Sellas as the REGAL Phase 3 readout remains pending.

Nasdaq, S&P 500, Dow Futures Rise Ahead Of Jobs Report: NKE, META, RKLB, MRNA, SLS, TSLA Stocks In Focus

Equity

On Stocktwits, retail sentiment toward SPY and QQQ remained ‘bullish’ ahead of jobs data.


Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before markets open on Oct.9.

SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027

Retail investors speculated that Sellas’ office lease through September 2027 provides stability for clinical results and potential deal discussions.

Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump? 

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%. 

Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch 

Novo has 44 abstracts at EASD, including CagriSema analyses and Phase 2b Zenagamtide results.

SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered

SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer vaccine in acute myeloid leukemia and a decision on whether SLS009 will advance into human trials for pancreatic cancer.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial 

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

Biotech Week Ahead: XLV Beats The Market — Here Are The Stocks, Readouts And Events To Watch Next 

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSPR NewswireNEW YORK, Sept. 17, 2026 NEW YORK, Sept. 17, 2026...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Neutral Sentiment

$TMDX

$SLS

Which of these trending stocks are you most tempted to buy - $ON, $TMDX, $SLS, or $BE?

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLS News